clinical-trials-head-neck-cancer-Opdivo-cw - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Experts sceptical on Bristol-Myers Squibb’s head and neck cancer trial of Opdivo

Bristol-Myers Squibb’s Phase III first-line head and neck squamous cell carcinoma (HNSCC) trial of Opdivo (nivolumab) and Yervoy (ipilimumab) is being met with scepticism while others said a prior failed trial makes conclusions tough. Credit: Minerva Studio / Shutterstock.